Chapter 1 · Growth
Detect dozens
of cancers from
one blood draw.
The product is potentially revolutionary. The revenue, so far, is tiny.
↓ scroll to read
✦ The bottom line
GRAIL sold $147M in 2025, growing ~28% year-over-year — small, because its Galleri test is still sold mostly out-of-pocket while it waits for FDA approval and insurance coverage. The bet isn't today's revenue; it's a future where screening healthy people for many cancers at once becomes routine.
↓ the brief below
✦ Teach me
Revenue before the market exists
GRAIL's Galleri test reads tiny fragments of DNA in your blood to look for a signal shared by many cancers — potentially flagging disease before any symptoms. Today most people who take it pay cash, because it isn't yet FDA-approved or covered by insurance.
So revenue is a trickle relative to the opportunity: if 'multi-cancer early detection' becomes a standard screening (like a mammogram or colonoscopy), the market is tens of millions of people. GRAIL is selling a glimpse of that future before it arrives.
Wall Street calls this
Revenue / pre-market
When revenue is tiny but the idea is huge, the income statement tells you almost nothing. What matters is the path to a real market — which runs through regulators and insurers (Chapter 6).
Revenue · fiscal year 2025
Up ~28% in the most recent quarter, but small — most Galleri tests are still paid out-of-pocket. The size of the business today is not the point; the size it *could* become is.
Source · 10-K · Results of Operations · FY2025 · Filed Mar 12, 2026